--Ocular Therapeutix, Inc., an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the first patient has been randomized in the HELIOS-3 Phase 3 ...
The MarketWatch News Department was not involved in the creation of this content. SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or ...
CEO Pravin Dugel described 2025 as "a transformative year for Ocular Therapeutix" and highlighted the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R. Dugel announced, "SOL-R has ...
The HELIOS program will be the first time an ordinal endpoint is being used in DR trials, which means the statistical analysis will account for both disease improvement and prevention of worsening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results